BROADCASTS.com

When asked what sets BioXcel Therapeutics apart from other clinical-stage biopharmaceutical companies, CFO Richard Steinhart doesn\u2019t mention a specific drug or therapy. Instead, he describes a system that the company developed to advance the speed with which drugs are commercialized.

According to Steinhart, the biotech company\u2019s system uses artificial intelligence to reveal \u201chidden connections\u201d that, once exposed, can multiply opportunities for the application of certain drugs.

\u201cGood drug developers can see first connections between drugs and diseases and they are pretty apparent to everyone out there, but second- and third-degree connections are not apparent,\u201d explains Steinhart, who says that such connections have been too time-consuming and expensive to expose in the past.

\u201cThe last company I was with took 10 years to go from the discovery (of a drug to the licensing of the discovery to a phase two trial,\u201d adds Steinhart, who reveals that it was BioXcel\u2019s system for shortening the path to commercialization that first attracted him. \u2013Jack Sweeney

Do you want to learn more about the experiences that shaped today\u2019s finance leaders?

GO PREMIUM with CFO Thought Leader and each quarter we will ship you our CFO Thought Leader Quarterly Magazine featuring profiles of 25 different CFOs (4 issues, per yr.). What\u2019s more, become a PREMIUM member before February 1, 2020 and we\u2019ll ship you THE CFO Yearbook 2020\xa0 featuring 100 CFO profiles. Go Premium today learn more